Breaking News

HPV 16/18 Vaccine Candidate Found 50% Effective

December 9, 2020 • 12:32 pm CST
(Vax Before Cancer)

INOVIO announced positive Phase 2 efficacy results demonstrating that DNA medicine VGX-3100, the company's lead immunotherapy asset, showed resolution of HPV-16/18-associated precancerous anal lesions in 50% of subjects 6-months following the start of treatment.